Niagen Bioscience, Inc.
NAGE
$4.78
-$0.04-0.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 103.30% | 1,275.69% | 1,411.32% | 499.80% | 273.15% |
| Total Depreciation and Amortization | -3.56% | -22.34% | -37.14% | -46.46% | -52.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,033.93% | -106.11% | -125.83% | -130.77% | -106.72% |
| Change in Net Operating Assets | -364.71% | 116.75% | 204.64% | 406.51% | -31.30% |
| Cash from Operations | 11.52% | 412.77% | 1,871.28% | 326.34% | 70.14% |
| Capital Expenditure | -79.14% | -126.09% | -177.00% | -57.14% | -10.14% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | 300.00% | 300.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -104.20% | -173.68% | -157.00% | -44.09% | 0.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.09% | -20.00% | -33.33% | 35.29% | 26.67% |
| Issuance of Common Stock | 33.39% | 558.68% | 1,856.52% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -28.85% | 38.37% | 38.37% | 45.35% | 30.67% |
| Cash from Financing | 28.81% | 595.40% | 2,213.12% | 8,340.78% | 6,065.56% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.11% | 466.97% | 2,103.45% | 534.06% | 151.82% |